ArticleFrontiers in pharmacology2018
Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.Pharmaceutical medicine · 2022Pooled it
- Governing AI for Pharmacovigilance in Low-Income Countries: Systems Perspective.Journal of medical Internet research · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).Scientific reports · 2024Article
- Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model.Therapeutic innovation & regulatory science · 2024Article
- Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Machine Learning in Causal Inference: Application in Pharmacovigilance.Drug safety · 2022Review
- High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases.Drug safety · 2022Article
- Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study.Frontiers in cardiovascular medicine · 2022Article
- New adaptive lasso approaches for variable selection in automated pharmacovigilance signal detection.BMC medical research methodology · 2021Article
- Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States.Frontiers in cardiovascular medicine · 2021Article
- Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.Frontiers in endocrinology · 2021Article
- Identifying Drugs Inducing Prematurity by Mining Claims Data with High-Dimensional Confounder Score Strategies.Drug safety · 2020Article
- Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical methods used for signal detection in pharmacovigilance rely on disproportionality analysis of counts aggregating spontaneous reports of a given adverse drug reaction. In recent years, alternative methods have been proposed to analyze individual spontaneous reports such as penalized multiple logistic regression approaches. These approaches address some well-known biases resulting from disproportionality methods. However, while penalization accounts for computational constraints due to high-dimensional data, it raises the issue of determining the regularization parameter and eventually that of an error-controlling decision rule. We present a new automated signal detection strategy for pharmacovigilance systems, based on propensity scores (PS) in high dimension. PSs are increasingly used to assess a given association with high-dimensional observational healthcare databases in accounting for confusion bias. Our main aim was to develop a method having the same advantages as multiple regression approaches in dealing with bias, while relying on the statistical multiple comparison framework as regards decision thresholds, by considering false discovery rate (FDR)-based decision rules. We investigate four PS estimation methods in high dimension: a gradient tree boosting (GTB) algorithm from machine-learning and three variable selection algorithms. For each (drug, adverse event) pair, the PS is then applied as adjustment covariate or by using two kinds of weighting: inverse proportional treatment weighting and matching weights. The different versions of the new approach were compared to a univariate approach, which is a disproportionality method, and to two penalized multiple logistic regression approaches, directly applied on spontaneous reporting data. Performance was assessed through an empirical comparative study conducted on a reference signal set in the French national pharmacovigilance database (2000-2016) that was recently proposed for drug-induced liver injury. Multiple regression approaches performed better in detecting true positives and false positives. Nonetheless, the performances of the PS-based methods using matching weights was very similar to that of multiple regression and better than with the univariate approach. In addition to being able to control FDR statistical errors, the proposed PS-based strategy is an interesting alternative to multiple regression approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.